• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

A Matter of Preference


Amsterdam, The Netherlands - Methotrexate and cyclosporine do not differ significantly in efficacy as systemic therapies for moderate to severe chronic plaque psoriasis, according to Menno de Rie, M.D., Ph.D., associate professor of dermatology at the University of Amsterdam. Dr. de Rie and colleagues compared the two therapies in a randomized study of 88 patients with moderate to severe psoriasis.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.